These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27362942)

  • 1. Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells.
    Hung MS; Chen IC; Lung JH; Lin PY; Li YC; Tsai YH
    PLoS One; 2016; 11(6):e0158395. PubMed ID: 27362942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo.
    Verone-Boyle AR; Shoemaker S; Attwood K; Morrison CD; Makowski AJ; Battaglia S; Hershberger PA
    Oncotarget; 2016 Jan; 7(1):995-1013. PubMed ID: 26654942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
    Li N; Li H; Su F; Li J; Ma X; Gong P
    Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
    Okabe T; Okamoto I; Tamura K; Terashima M; Yoshida T; Satoh T; Takada M; Fukuoka M; Nakagawa K
    Cancer Res; 2007 Mar; 67(5):2046-53. PubMed ID: 17332333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
    Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
    J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.
    Hung MS; Chen IC; Lin PY; Lung JH; Li YC; Lin YC; Yang CT; Tsai YH
    Oncol Lett; 2016 Dec; 12(6):4598-4604. PubMed ID: 28101216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
    Gadgeel SM; Ali S; Philip PA; Ahmed F; Wozniak A; Sarkar FH
    Cancer; 2007 Dec; 110(12):2775-84. PubMed ID: 17948911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T; Lowell AM; Engelman JA; Shapiro GI
    Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
    Okamoto K; Okamoto I; Okamoto W; Tanaka K; Takezawa K; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
    Cancer Res; 2010 Dec; 70(24):10402-10. PubMed ID: 21159653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of CDH1 up-regulates epidermal growth factor receptor via phosphorylation of YBX1 in non-small cell lung cancer cells.
    Liu X; Su L; Liu X
    FEBS Lett; 2013 Dec; 587(24):3995-4000. PubMed ID: 24211838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.
    Akca H; Tani M; Hishida T; Matsumoto S; Yokota J
    Lung Cancer; 2006 Oct; 54(1):25-33. PubMed ID: 16872715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
    Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP
    Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
    Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
    Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.